# JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05490472/  
OnCo record `nct05490472` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JAB-2485 (Aurora A inhibitor) in triple-negative breast cancer and small-cell lung cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.

## Summary

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05490472 by Jacobio Pharmaceuticals Co., Ltd., with 102 participants planned, started 2022-12-20 and due to reach its primary completion in 2026-08. Interventions recorded: JAB-2485 (Aurora A inhibitor).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05490472
- Phase: 1/2
- Setting: A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors
- Sponsor: Jacobio Pharmaceuticals Co., Ltd.
- Enrolled: 102

## Sources

- ClinicalTrials.gov NCT05490472: https://clinicaltrials.gov/study/NCT05490472

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [Jacobio Pharmaceuticals](https://onco.cc/companies/jacobio-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct05490472.json